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ABSTRACT  
This study evaluated the dosimetric difference between volumetric-modulated arc 
therapy (VMAT) and conventional fixed-field intensity-modulated radiotherapy 
(cIMRT) in whole-ventricular irradiation. Computed tomography simulation data for 13 
patients were acquired to create plans for VMAT and cIMRT. In both plans, the same 
median dose (100% = 24 Gy) was prescribed to the planning target volume (PTV), 
which comprised a tumor bed and whole ventricles. During optimization, doses to the 
normal brain and body were reduced, provided that the dose constraints of the target 
coverage were satisfied. The dose-volume indices of the PTV, normal brain, and body 
as well as monitor units were compared between the two techniques by using paired 
t-tests. The results showed no significant difference in the homogeneity index (0.064 vs. 
0.065; p = 0.824) of the PTV and conformation number (0.78 vs. 0.77; p = 0.065) 
between the two techniques. In the normal brain and body, the dose-volume indices 
showed no significant difference between the two techniques, except for an increase in 
the volume receiving a low dose in VMAT; the absolute volume of the normal brain and 
body receiving 1 Gy significantly increased in VMAT by 1.6% and 8.3%, respectively, 
compared with that in cIMRT (1044 vs. 1028 mL for the normal brain and 3079.2 vs. 
2823.3 mL for the body; p <0.001). The number of monitor units to deliver a 2.0-Gy 
   
fraction was significantly reduced in VMAT compared with that in cIMRT (354 vs. 873, 
respectively; p <0.001). In conclusion, VMAT delivers IMRT to complex target 
volumes such as whole ventricles with fewer monitor units, while maintaining target 
coverage and conformal isodose distribution comparable to cIMRT; however, in 
addition to those characteristics, the fact that the volume of the normal brain and body 
receiving a low dose would increase in VMAT should be considered.  





   
Introduction  
Whole-ventricular irradiation (WVI) has been indispensable to high local/regional control and 
survival rates in patients with localized intracranial germinoma.1 Intensity-modulated 
radiotherapy (IMRT) is an advanced radiation technique that delivers a conformal dose to the 
target and spares organs at risk (OARs). In WVI, conventional fixed-field IMRT (cIMRT) has 
shown dosimetric advantages in normal tissue sparing.2-5 Sparing normal tissue is considered 
helpful in sustaining cognitive function and social status in long-term survivors with brain 
tumors that originate during childhood.6 In addition to the advantage regarding OARs, WVI 
using cIMRT has been reported to improve target coverage,5 which can be important in 
controlling a tumor. WVI using cIMRT may reduce late side effects related to radiotherapy 
without compromising local/regional control for patients with localized intracranial 
germinoma.  
 Volumetric-modulated arc therapy (VMAT), developed by Otto,7 is now 
commercially available as the RapidArc system (Varian Medical Systems, Palo Alto, CA). 
RapidArc can deliver IMRT with dynamic arcs by changing three mechanical parameters: the 
   
gantry rotation speed, multi-leaf collimator motion, and dose rate. The mechanical 
characteristics of RapidArc result in IMRT with fewer monitor units while maintaining target 
coverage and OAR sparing that are comparable to cIMRT in planning studies of primary 
intracranial tumors.8-10 In WVI, VMAT is expected to reduce monitor units without 
compromising plan quality, compared with cIMRT; however, to our knowledge, no 
information is available regarding the planning comparison between VMAT and cIMRT in 
WVI. One published report of VMAT in WVI was a comparison between VMAT and 
three-dimensional conformal radiotherapy. 11 The aim of the present study was to reveal the 
dosimetric differences in WVI between plans using VMAT with the RapidArc system and 
those using cIMRT. 
 
Methods and materials  
Patient characteristics 
The present study included 13 patients, who underwent radiotherapy following induction 
chemotherapy for localized intracranial germinoma at Kyoto University Hospital between 
   
June, 2003 and March, 2010. Induction chemotherapy yielded a complete response in all 
patients enrolled in the current study. Computed tomography (CT) simulation and magnetic 
resonance imaging data for 12 of 13 patients were acquired previously for a dosimetric 
comparison between three-dimensional conformal radiotherapy and cIMRT.5 Data for one 
female patient with bifocal localized intracranial germinoma were added to the present study. 
Details of the CT simulation and the delineation of the planning target volume (PTV) were 
described previously.5 In the present study, the normal brain, body, and lens were delineated 
as the OARs. The normal brain was defined as the brain volume outside the PTV. The region 
scanned in the CT simulation was from the top of the head to the neck, which was sufficient 
to include the irradiated volume. The mean age was 17.5 years (range, 5–34 years). The 
primary sites were the pineal region (n = 4), suprasellar region (n = 5), and bifocal region 
(pineal and suprasellar; n = 4). The mean volumes of the tumor bed, whole ventricles, PTV, 
normal brain, and body were 3.6 mL (range, 0.1−15.6 mL), 52.9 mL (range, 33.3−84 mL), 
363.4 mL (range, 295.7−425.0 mL), 1048.4 mL (range, 759.3−1210.3 mL), and 4923.5 mL 
(range, 3724−9549.2 mL), respectively.  
   
Treatment planning 
Treatment planning for VMAT and cIMRT was performed using Eclipse (ver. 8.6.15; Varian 
Medical Systems, Palo Alto, CA). All treatment plans were created with 6-MV photon beams, 
commissioned for a Varian CL21iX linear accelerator and Millennium 120-leaf multi-leaf 
collimator (Varian Medical Systems). Dose calculation was performed using the anisotropic 
analytical algorithm12 with a calculation grid of 2.5 mm. The isocenter was placed in the 
center of the PTV.  
 The cIMRT plans consisted of seven coplanar fields with angles of 0, 55, 105, 155, 
205, 255, and 305°. The Varian’s Eclipse fluence-based algorithm was used in the 
optimization. Multi-leaf collimator leaf sequences were generated using the dynamic 
sliding-window technique.13 The accuracy of cIMRT dose delivery is affected by the dose rate, 
although a higher dose rate can theoretically reduce the beam-on time in cIMRT.14 We set 
the dose rate for cIMRT as 300 monitor units/min, which is the dose rate adopted for cIMRT 
plans using the dynamic sliding-window technique at our hospital.  
   
 VMAT plans were created for the RapidArc system (Varian Medical Systems) with 
coplanar double arcs, because RapidArc with a single arc has difficulty in achieving 
conformal dose distribution for complex target volumes.15 One arc rotation was clockwise, 
from -179 to 179°, and the other was counter-clockwise, from 179 to -179°. The couch 
position was set at 0°. The collimator angles were 45° and 315° in each arc. The maximal 
dose rate and maximal gantry speed were set as 600 monitor units/min and 4.8°/s, respectively. 
The coplanar double arcs were optimized simultaneously.  
 For optimization, dose constraints were prioritized to satisfy the target coverage 
requirement: D98% (DX% represents the dose covering X% of the structure volume) to the 
PTV was larger than 98% of the prescribed dose (100% = 24 Gy in 12 fractions), and D2% to 
the PTV was lower than 107% of the prescribed dose. The planning objectives were set for 
identical structures; PTV and normal brain, however the parameters for optimization were 
individually set for each patients to make conformal isodose distribution to the PTV. Provided 
that the target objectives were satisfied, D2% and the median dose (D50%) to the normal 
brain were reduced. After optimization, the value of D50% to the PTV in the VMAT plan was 
   
normalized to the same value as that in cIMRT. When the dose indices violated the 
constraints after the normalization process, optimization of the VMAT plan was restarted 
until the dose constraints of the PTV were satisfied.  
Assessment of endpoints 
The mean dose-volume histograms (DVHs) of the PTV, normal brain, and body were created 
from the dose-volume data of 26 cIMRT and VMAT plans. To compare the target coverage, 
D2%, D98%, and the homogeneity index (HI) were calculated. HI was defined as 
(D2%−D98%)/D50% 16. For the normal brain and body, D50%, and the volume receiving 18, 
12, 6, 3, and 1 Gy (V18Gy, V12Gy, V6Gy, V3Gy, and V1Gy) were compared between the two 
techniques. Additionally, D2% in the normal brain was evaluated. D50% was used to 
compare the dose to the lens between the two techniques. Conformity was evaluated by the 
conformation number (CN).17 The CN was defined as (TVRI/TV) × (TVRI/VRI), where TVRI = 
the target volume covered by the reference isodose, TV = target volume, and VRI = the 
volume of the reference isodose. The 95% isodose was used as the reference isodose in the 
present study. To compare the quality of our plan with that of a previous study,5 we also 
   
evaluated the maximal dose (Dmax), D95%, D99%, and the percentage volume receiving 
100% of the prescribed dose (V100%) of the PTV, as calculated in the previous study. The 
numbers of monitor units to deliver a 2-Gy fraction were calculated for both techniques. 
Statistical analysis 
The HIs of the PTV, CN, V18Gy, V12Gy, V6Gy, V3Gy, and V1Gy, and the numbers of monitor 
units were compared between cIMRT and VMAT using paired t-tests. All statistical tests 
were two-sided. A p-value less than 0.05 was deemed to indicate statistical significance. 
Statistical analyses were conducted using Graphpad software (ver. 5.03; Graphpad Software, 
San Diego, CA).  
 
Results  
Target coverage  
The mean D50% to the PTV was 102.4% (range, 101.9−103.1%) of the prescribed dose in 
both techniques. No significant differences in HI or CN were observed between cIMRT and 
VMAT (0.064 vs. 0.065, respectively, for the HI [p = 0.824] and 0.78 vs. 0.77 respectively, 
   
for the CN [p = 0.065]). Both techniques resulted in a conformal isodose distribution to the 
PTV (Fig. 1). The shapes of the mean DVH of the PTV were similar in cIMRT and VMAT 
(Fig. 2). The mean D2%, D98%, D95% values to the PTV, and V100% of the PTV (standard 
deviation) were: 104.8% (0.3) vs. 105.3% (0.5), 98.2% (0.2) vs. 98.7% (0.4), 99.6% (0.2) vs. 
99.9% (0.3) and 93.3% (1.1) vs. 93.9% (1.5), respectively, in cIMRT and VMAT. The 
absolute differences in these dose indices between the two techniques were 0.3−1.9% of the 
prescribed dose.  
 
Dose to organs at risk 
No significant difference was observed between cIMRT and VMAT regarding D50% to the 
normal brain (63.2% vs. 62.5%, respectively; p = 0.137) and body (14.6% vs. 14.3%, 
respectively; p = 0.549). The shapes of the mean DVH of the normal brain and body were 
generally similar in cIMRT and VMAT, except for the volume that received a low dose, 
which was larger in VMAT than in cIMRT (Fig. 2 and Table 1). The V1Gy values for the 
normal brain and body were significantly higher in VMAT; however, the V3Gy and V6Gy 
   
values for the normal brain and body were significantly lower in VMAT than in cIMRT. The 
absolute increases in V1Gy in the normal brain and body were 16 and 256.0 mL, respectively. 
The absolute decreases in V3Gy and V6Gy were 5.0 and 10.1 mL, respectively, in the normal 
brain, and 21.0 and 41.0 mL, respectively, in the body. The D50% to the lens (standard 
deviation) was significantly higher in VMAT than in cIMRT (1.6 Gy (0.90) vs. 1.2 Gy (0.72), 
respectively; p <0.001). The mean number of monitor units to deliver a 2.0-Gy fraction was 
significantly higher in cIMRT than in VMAT (873 vs. 354, respectively; p <0.001).  
 
Discussion  
VMAT remains a developing technique compared with cIMRT. The shape of whole 
ventricles includes concave and convex contours. It has been reported that large or complex 
target volumes cause difficulties in creating VMAT plans that are comparable to those for 
cIMRT.8,9 Moreover, the quality of the required plan influences the feasibility of VMAT.18 In 
WVI for localized intracranial germinoma, high-quality planning is essential because 
sufficient target coverage of complex target volumes is indispensable for high local/regional 
   
control and overall survival.19 We previously reported dose indices of the PTV achieved in 
WVI using conventional three-dimensional conformal radiotherapy.5 Compared with that 
report, the dose indices in the present study show comparable target coverage; the absolute 
differences in Dmax, D95%, D99%, and V100% of the PTV between the present and 
previous reports are less than 1−3% of the prescribed dose. As shown in Fig. 1, together with 
adequate target coverage, the conformal isodose distribution to the PTV spares the normal 
brain. In WVI, VMAT using double arcs can deliver conformal dose distribution to the PTV 
while maintaining adequate target coverage, which was comparable to that of cIMRT. 
 The present study focused on low-dose exposure of the normal brain and body within 
the irradiation field in VMAT. The whole ventricles were centrally located and surrounded by 
normal brain and body. In VMAT, the beam reaches the target from multiple angles, 
presenting the risk of spreading the dose to surrounding normal tissue within the irradiation 
field. In fact, the current study revealed an increase in low-dose exposure within the 
irradiation field in VMAT, compared with cIMRT. Intracranial germ cell tumors are most 
often found in patients in the early pubertal years.20 The effects of increased low-dose 
   
exposure on normal surrounding tissue raise concerns regarding carcinogenesis. Hence, for 
clinical use of VMAT, we should consider the dosimetric character: the volume of the normal 
brain and body within the irradiation field that receives a low dose is higher in VMAT.  
 In the present study, the increased volume receiving a low dose in the normal brain 
and body was limited to V1Gy. Although a biological discussion is not the major focus of the 
current paper, the biological impact in terms of carcinogenesis has been reported to be lower 
for low-dose exposure than for high-dose exposure.21 Tubiana suggested that potent defenses 
against the carcinogenic effects of ionizing radiation were more effective at low doses, based 
on animal and human data.21 Some authors have reported that a dose per fraction of less than 
120 to 160 mGy cumulating to about 3 Gy caused less carcinogenesis than higher doses per 
fraction.22, 23 The effects of the observed increase of V1Gy are small, which would be 
counterbalanced by the decrease in V6Gy and V3Gy in the normal brain and body. We believe 
that use of VMAT can be justified provided that the increased irradiated volume of the normal 
surrounding tissue is limited to the low-dose volume, as observed in the current study.  
   
 In this study, the different dose rates were used in each technique. In VMAT, the 
higher dose rates achieved the smaller number of monitor units by the compensation of gantry 
speed and multi leaf collimator motion.24, 25 Thus in VMAT, we selected the maximal dose 
rate as 600 monitor units/min which was the maximally available dose rate from the previous 
reports. Differently from VMAT, the dose rate is basically unchanged through beam-on time 
in cIMRT. It was reported that the higher the dose rates were, the larger the number of 
monitor units was in cIMRT.26 The number of monitor units is associated with the amount of 
transmitted radiation dose through the multi leaf collimator and the treatment time. 
Considering our clinical practice and published paper’s recommendation, we set the dose 
rates as 300 monitor units/min for cIMRT, although it was smaller dose rate than in VMAT. It 
is important to select the optimal dose rate in VMAT and cIMRT planning, reflecting that the 
dosimetric effects from the dose rates differed between two techniques.  
The longer beam-on time in cIMRT increases the exposure of normal tissue to low 
doses outside the irradiation field,27 as confirmed by dosimetric studies.4,28 For instance, 
Mansur et al. reported that the dose outside the irradiation field was 1–10 cGy higher in 
   
cIMRT than in conventional radiotherapy when 54 Gy were delivered in 30 fractions to a 
phantom of a young patient with an intracranial tumor.28 Matuszak et al. emphasized that 
VMAT reduces low-dose exposure outside the irradiation field because it requires fewer 
monitor units.29 They hypothesized that the reduced low-dose exposure may alleviate 
concerns regarding secondary malignancies in young patients. Most importantly, dose 
reduction outside the irradiation field is desirable; however, the reported absolute dose 
reduction outside the irradiation field is relatively small compared with that inside the 
irradiation field. Biologically, low-dose exposure has been reported to have a minimal impact 
on carcinogenesis.21 In fact, 78% of secondary malignancies occur in the area within or 
surrounding the PTV,30 where the higher dose is prescribed. Thus, we believe that in 
considering VMAT planning the focus should be on dose exposure within, rather than outside, 
the irradiation field. 
 The lens is particularly sensitive to radiation. The threshold dose for cataract 
formation has been reported to be 2–10 Gy.31 The lens is located in the peripheral region of 
the irradiation field, where VMAT may increase low-dose exposure. In previous reports on 
   
the use of RapidArc for intracranial tumors, the lens received more than 10% of the 
prescribed dose.10,32 In the present study, the total dose received by the lens was maintained 
below 2 Gy, which was 6.6% of the dose prescribed in the VMAT plans. It is thought that the 
reduced dose to the lens was the result of tilting the patient’s head during the radiotherapy 
treatment. In the CT data used in the present study, the patients were supine with the head 
tilted, which facilitated sparing of the lens, as was found in a previous study in which a 
head-tilted technique was used.9 Our results support the feasibility of sparing the lens in 
VMAT using the RapidArc system.  
 In conclusion, VMAT delivers IMRT to a complex target volume, such as whole 
ventricles, with fewer monitor units while maintaining target coverage and OAR sparing 
comparable to cIMRT. However, the fact that a greater volume of the normal brain and body 
within the irradiation field receives a low dose in VMAT should be considered when 
planning. 
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Fig. 1.   Multi-plane slices showing isodose distribution for cIMRT and VMAT. 
 
Shaded cyan area = tumor bed before induction chemotherapy; shaded red area = planning 
target volume. Yellow line indicates 100%; green, 95%; light blue, 90%; dark blue, 80%; 
orange, 70%; and pink, 50% of the isodose line. 
 
Abbreviations:  cIMRT = conventional fixed-field intensity-modulated radiotherapy; VMAT 
= volumetric-modulated arc therapy using the RapidArc system. 
   
Fig. 2.   Mean cumulative dose-volume histograms of the PTV, normal brain*, and body. 
 
Abbreviations: PTV = planning target volume; cIMRT = conventional fixed-field 
intensity-modulated radiotherapy; VMAT = volumetric-modulated arc therapy using the 
RapidArc system. 
Foot notes: * normal brain = the volume of the brain outside the PTV. 
   
Table 
Table 1. Summary of dose-volume histogram analysis of the PTV, normal brain*, and body 
(mean value [standard deviation]). 
  cIMRT VMAT Difference p† 
PTV     
 Homogeneity index‡ 0.064 (0.004) 0.065 (0.006) +0.001 0.824 
Normal brain     
 D2% (%) 100.1 (0.7) 100.8 (0.8) +0.7 0.024 
 D50% (%) 63.2 (3.1) 62.5 (2.9) −0.7 0.137 
 V18Gy (mL) 316.9 (35.8) 313.3 (32.5) −3.6 0.540 
 V12Gy (mL) 737.1 (67.8) 741.6 (75.1) +4.5 0.586 
 V6Gy (mL) 880.2 (92.9) 870.1 (88.7) −10.1 0.004 
 V3Gy (mL) 919.2 (97.9) 914.2 (94.5) −5.0 0.049 
 V1Gy (mL) 1028.0 (119.1) 1044.0 (130.2) +16.0 0.027 
Body     
   
 D50% (%) 14.6 (10.3) 14.3 (9.1) −0.3 0.549 
 V18Gy (mL) 725.2 (57.7) 719.7 (60.1) −5.5 0.395 
 V12Gy (mL) 1352.0 (114.3) 1351.9 (125.6) −0.1 0.996 
 V6Gy (mL) 2053.2 (233.2) 2012.0 (227.0) −41.0 <0.001 
 V3Gy (mL) 2323.9 (312.5) 2303.5 (312.4) −21.0 <0.001 
 V1Gy (mL) 2823.3 (396.5) 3079.2 (427.6) +256.0 <0.001 
Conformation  number# 0.78 (0.034) 0.77 (0.034) −0.01 0.065 
Monitor units 873.1 (95.1) 354.1 (28.3) −519.0 <0.001 
Abbreviations: PTV = planning target volume; cIMRT = conventional fixed-field 
intensity-modulated radiotherapy; VMAT = volumetric-modulated arc therapy using the 
RapidArc system; DX% = the dose that covers X% of the structure volume; VXGy = the 
absolute volume receiving X Gy.  
 
Footnotes: * normal brain = the volume of the brain outside the PTV; † p-value with paired 
t-test; ‡ homogeneity index = (D2%−D98%)/D50% 15; # conformation number = (TVRI/TV) × 
   
(TVRI/VRI), where TVRI = the target volume covered by the reference isodose, TV = target 
volume, and VRI = the volume of the reference isodose16 The 95% isodose was used for the 
reference isodose 
cIMRT VMAT
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